ABSTRACT - 598323 The disclosure relates to solid pharmaceutical dosage form comprising the SGLT-2 inhibitor 1-chloro-4-(&bgr；-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy-benzyl]-benzene, the partner drug metformin hydrochloride, and one or more pharmaceutical excipients, wherein the SGLT-2 inhibitor is present in a dosage range from about 1 mg to about 25 mg, and wherein metformin hydrochloride is present in a dosage range from about 100 mg to about 1500 mg, and wherein the pharmaceutical excipients are selected from the group consisting of one of more fillers selected from the group consisting of microcrystalline cellulose (MCC)； D-mannitol, corn starch and pregelatinized starch； a binder selected from the group consisting of copovidone. Said solid dosage form is suitable for treating a metabolic disorder selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, impaired fasting blood glucose, hyperglycemia, postprandial hyperglycemia, overweight, obesity and metabolic syndrome.
